Literature DB >> 24683450

A peptide-free, liposome-based oligosaccharide vaccine, adjuvanted with a natural killer T cell antigen, generates robust antibody responses in vivo.

S Deng1, L Bai2, R Reboulet3, R Matthew3, D A Engler4, L Teyton1, A Bendelac3, P B Savage1.   

Abstract

Due to the prevalence of oligo- and polysaccharides on the surfaces of pathogenic organisms, carbohydrates are primary targets for recognition by antibodies generated by the immune systems of higher organisms. Consequently, substantial effort has been expended in efforts to develop vaccines based on carbohydrate epitopes. Typical approaches involve multivalent presentation of carbohydrate targets on antigenic peptides or proteins, which often involve substantial synthetic commitments and/or vaccines that are heterogeneous and difficult to characterize. We have developed a simple, liposome-based approach to generate multivalent carbohydrate vaccines, and in place of an antigenic peptide or protein, we have used a potent antigen for natural killer T cells. This vaccine, based on the Streptococcus pneumoniae serotype 14 polysaccharide, gave a response superior to that from a clinically used vaccine (Prevnar). The dependence of this response on liposome formation was demonstrated by comparison to a simple mixture of the oligosaccharide and the natural killer T cell adjuvant. The importance of the strength of the adjuvant was observed by use of a potent synthetic adjuvant and a weaker, bacterial derived glycolipid adjuvant. These results demonstrate the effectiveness of this novel and relatively simple means of generating carbohydrate-based vaccines.

Entities:  

Year:  2014        PMID: 24683450      PMCID: PMC3966715          DOI: 10.1039/C3SC53471E

Source DB:  PubMed          Journal:  Chem Sci        ISSN: 2041-6520            Impact factor:   9.825


  16 in total

1.  Chemo-enzymatic synthesis of a tetra- and octasaccharide fragment of the capsular polysaccharide of Streptococcus pneumoniae type 14.

Authors:  John A F Joosten; Johannis P Kamerling; Johannes F G Vliegenthart
Journal:  Carbohydr Res       Date:  2003-11-14       Impact factor: 2.104

Review 2.  Bacterial capsular antigens. Structural patterns of capsular antigens.

Authors:  Yu S Ovodov
Journal:  Biochemistry (Mosc)       Date:  2006-09       Impact factor: 2.487

3.  Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides.

Authors:  Li Bai; Shenglou Deng; Rachel Reboulet; Rebecca Mathew; Luc Teyton; Paul B Savage; Albert Bendelac
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

4.  Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.

Authors:  Kristina A Bryant; Stan L Block; Sherryl A Baker; William C Gruber; Daniel A Scott
Journal:  Pediatrics       Date:  2010-05       Impact factor: 7.124

5.  A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells.

Authors:  Yang Liu; Randal D Goff; Dapeng Zhou; Jochen Mattner; Barbara A Sullivan; Archana Khurana; Carlos Cantu; Eugene V Ravkov; Chris C Ibegbu; John D Altman; Luc Teyton; Albert Bendelac; Paul B Savage
Journal:  J Immunol Methods       Date:  2006-03-06       Impact factor: 2.303

Review 6.  Progress toward a Staphylococcus aureus vaccine.

Authors:  Robert S Daum; Brad Spellberg
Journal:  Clin Infect Dis       Date:  2011-12-20       Impact factor: 9.079

Review 7.  Cancer vaccines and carbohydrate epitopes.

Authors:  Jamie Heimburg-Molinaro; Michelle Lum; Geraldine Vijay; Miten Jain; Adel Almogren; Kate Rittenhouse-Olson
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

Review 8.  Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease.

Authors:  W P Hausdorff; R Dagan; F Beckers; L Schuerman
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

9.  Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14.

Authors:  Dodi Safari; Huberta A T Dekker; John A F Joosten; Dirk Michalik; Adriana Carvalho de Souza; Roberto Adamo; Martina Lahmann; Andreas Sundgren; Stefan Oscarson; Johannis P Kamerling; Harm Snippe
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

Review 10.  Immune responses to polysaccharides: lessons from humans and mice.

Authors:  Africa González-Fernández; Jose Faro; Carmen Fernández
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

View more
  9 in total

Review 1.  Recent advances in synthetic carbohydrate-based human immunodeficiency virus vaccines.

Authors:  Zhenyuan Wang; Chunjun Qin; Jing Hu; Xiaoqiang Guo; Jian Yin
Journal:  Virol Sin       Date:  2016-03-17       Impact factor: 4.327

Review 2.  Recent advances on smart glycoconjugate vaccines in infections and cancer.

Authors:  Marko Anderluh; Francesco Berti; Anna Bzducha-Wróbel; Fabrizio Chiodo; Cinzia Colombo; Federica Compostella; Katarzyna Durlik; Xhenti Ferhati; Rikard Holmdahl; Dragana Jovanovic; Wieslaw Kaca; Luigi Lay; Milena Marinovic-Cincovic; Marco Marradi; Musa Ozil; Laura Polito; Josè Juan Reina; Celso A Reis; Robert Sackstein; Alba Silipo; Urban Švajger; Ondřej Vaněk; Fumiichiro Yamamoto; Barbara Richichi; Sandra J van Vliet
Journal:  FEBS J       Date:  2021-06-01       Impact factor: 5.622

3.  Small Wonders-The Use of Nanoparticles for Delivering Antigen.

Authors:  Aya Taki; Peter Smooker
Journal:  Vaccines (Basel)       Date:  2015-08-10

Review 4.  Role of non-conventional T lymphocytes in respiratory infections: the case of the pneumococcus.

Authors:  Stoyan Ivanov; Christophe Paget; François Trottein
Journal:  PLoS Pathog       Date:  2014-10-09       Impact factor: 6.823

5.  Fully Synthetic Self-Adjuvanting α-2,9-Oligosialic Acid Based Conjugate Vaccines against Group C Meningitis.

Authors:  Guochao Liao; Zhifang Zhou; Sharad Suryawanshi; Mohabul A Mondal; Zhongwu Guo
Journal:  ACS Cent Sci       Date:  2016-04-04       Impact factor: 14.553

Review 6.  Natural Killer T Cells and Mucosal-Associated Invariant T Cells in Lung Infections.

Authors:  François Trottein; Christophe Paget
Journal:  Front Immunol       Date:  2018-08-02       Impact factor: 7.561

7.  The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.

Authors:  Yonghui Liu; Zhaoyu Wang; Fan Yu; Mingjing Li; Haomiao Zhu; Kun Wang; Meng Meng; Wei Zhao
Journal:  Int J Nanomedicine       Date:  2021-01-14

8.  Recyclable fluorous-tag assisted two-directional oligosaccharide synthesis enabled by interrupted Pummerer reaction mediated glycosylation.

Authors:  Lei Cai; Qi Chen; Jian Guo; Zhihua Liang; Dengxian Fu; Lingkui Meng; Jing Zeng; Qian Wan
Journal:  Chem Sci       Date:  2022-06-22       Impact factor: 9.969

Review 9.  Immunobiology of Carbohydrates: Implications for Novel Vaccine and Adjuvant Design Against Infectious Diseases.

Authors:  Giuseppe Stefanetti; Francesco Borriello; Barbara Richichi; Ivan Zanoni; Luigi Lay
Journal:  Front Cell Infect Microbiol       Date:  2022-01-18       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.